Kitabis Pak

August 25, 2015November 5, 2015

Kitabis Pak Named 1 Of The 10 Notable Drug-Device Approvals Of 2014

Cystic Fibrosis, News

Kitabis Pak, the first co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer to address cystic fibrosis, was recently listed among ten notable drug-device approvals of 2014, published in ... Read more

July 23, 2015November 5, 2015

Access To PARI’s Kitabis Pak CF Therapy Expanded To State Healthcare Programs in U.S.

Cystic Fibrosis, News

PARI, the makers of cystic fibrosis nebulized antibiotic therapy Kitabis Pak, have announced that the product has been added to state healthcare systems across the United States, and now belongs to the Preferred Drug List (PDL) for multiple state ... Read more

March 19, 2015November 5, 2015

FDA Lists Kitabis Pak As TOBI Equivalent Therapeutic in Cystic Fibrosis

Cystic Fibrosis, News

The FDA has listed Kitabis™ Pak as an equivalent therapy to TOBI® (tobramycin inhalation solution, USP) in their “Orange Book” (an FDA-published guideline for equivalent therapies). Kitabis Pak is listed under the “AN” ... Read more

February 17, 2015November 5, 2015

PARI PROVIDE Program Gives Kitabis Pak CF Users Access to FDA-Approved Compressors for Bacterial Infection Treatment

Cystic Fibrosis, News

PARI, a company working on the development and commercialization of effective aerosol delivery systems (drug and device) for patients suffering from respiratory disorders like cystic fibrosis, chronic lung disease and asthma, has announced ... Read more

December 4, 2014November 5, 2015

FDA Approves PulmoFlow’s CF Combined Therapy of Drug and Nebulizer

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) has announced that Kitabis Pak, a co-packaging of generic tobramycin inhalation solution with the PARI LC PLUS Nebulizer developed by PulmoFlow, Inc. has been granted final approval. ... Read more